Authors

HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Struggling With COVID-19 on the Cancer Floor

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Career Options for Graduating Oncology Fellows at the NIH and FDA

Peter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.

Biology, Compassion, and Patience Motivate Stock as a Pioneer in Leukemia

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

Dr Mar on Challenges With ARPI Rechallenge in Prostate Cancer

Nataliya Mar, MD, discusses attempts to develop mechanisms for resensitizing prostate tumors to ARPI rechallenge.

Kay Macleod Named Associate Director for Basic Sciences for the Cancer Center

Kay Macleod, PhD, has been appointed as the associate director for Basic Sciences for the University of Chicago Medicine Comprehensive Cancer Center.

Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities

Henry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Gymnastics Makes Me a Better Oncologist

Valentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.

ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy

The Association of Community Cancer Centers announced that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.

Smoking Cessation Support Plays a Vital Role in Improving Lung Cancer Screening

Results of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Nogapendekin Alfa Inbakicept Plus BCG Favored Over Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026

Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.

ChatGPT, M.D.? Evaluating Chatbot Accuracy in the Fast-Changing Blood Cancer Field

Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Integrating New Standards for Metastatic HER2+ Breast Cancer

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Our Path Forward in Leading a Revolution in Cancer Care

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Hackensack Meridian Health Partners with DELFI Diagnostics, Supported by a Grant from Lilly to Improve Lung Cancer Screening Adherence With Innovative Blood Test

The initiative aims to increase uptake of life-saving LDCT scans for high-risk individuals in line with guidance via a minimally invasive blood test.

Extending Overall Survival in Patients with Advanced Urothelial Carcinoma

ADC Cast: ADC antigen targets: What are we aiming at?

This is a featured episode from an educational podcast series with expert discussions on antibody drug conjugates, intended for US healthcare professionals.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

New Treatment May Dramatically Improve Survival for Those With Deadly Brain Cancer

Keck Medicine of USC researchers found a potential way to break the blood-brain barrier to improve immune checkpoint inhibitor efficacy in recurrent, high-grade astrocytoma.

CAR T Pioneers Describe Challenges Faced in Cancer

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research Forward

The use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.